Cargando…

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya

BACKGROUND: During the 2014 West African Ebola outbreak, Ebola vaccine development was accelerated. The phase 1 VAC52150EBL1003 study was performed to investigate 2-dose heterologous vaccination with Ad26.ZEBOV and MVA-BN-Filo in an African population located in a high-altitude setting in Nairobi, K...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mutua, Gaudensia, Anzala, Omu, Luhn, Kerstin, Robinson, Cynthia, Bockstal, Viki, Anumendem, Dickson, Douoguih, Macaya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548899/ https://www.ncbi.nlm.nih.gov/pubmed/30796816 http://dx.doi.org/10.1093/infdis/jiz071

Ejemplares similares

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
por: Bockstal, Viki, et al.
Publicado: (2021)

Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Alexandre, Marie, et al.
Publicado: (2023)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
por: Anywaine, Zacchaeus, et al.
Publicado: (2019)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
por: Anywaine, Zacchaeus, et al.
Publicado: (2022)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
por: Barry, Houreratou, et al.
Publicado: (2021)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
por: Afolabi, Muhammed O, et al.
Publicado: (2022)

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study
por: Bockstal, Viki, et al.
Publicado: (2022)

1049. Minimal Transient HIV-1 Viremia Following Vaccination Regimens Containing AD26. ZEBOV and MVA-BN-Filo in ART-Suppressed People Living with HIV
por: Custer, Benjamin L, et al.
Publicado: (2021)

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
por: Ishola, David, et al.
Publicado: (2022)

Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children( )
por: Ishola, D
Publicado: (2022)

Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign
por: Nyombayire, Julien, et al.
Publicado: (2022)

Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya
por: Nyaoke, Borna A., et al.
Publicado: (2017)

Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial
por: Karita, Etienne, et al.
Publicado: (2022)

The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen
por: Manno, Daniela, et al.
Publicado: (2023)

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study
por: Goldstein, Neil, et al.
Publicado: (2020)

Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda
por: Kitonsa, Jonathan, et al.
Publicado: (2020)

NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans
por: Wagstaffe, Helen R., et al.
Publicado: (2022)

Durable natural killer cell responses after heterologous two-dose Ebola vaccination
por: Wagstaffe, Helen R., et al.
Publicado: (2021)

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
por: Shukarev, Georgi, et al.
Publicado: (2016)

Cultured enzyme-linked immunospot assay (ELISPOT) enhances detection of low HIV-specific immune responses in exposed seronegative individuals in Kenya
por: Muturi, Margaret, et al.
Publicado: (2006)

Willingness to participate in future HIV vaccine trials among men who have sex with men and female sex workers living in Nairobi, Kenya
por: Mutisya, Elizabeth Mueni, et al.
Publicado: (2020)

Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination
por: Wagstaffe, Helen R, et al.
Publicado: (2019)

Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation
por: Pasin, Chloé, et al.
Publicado: (2019)

Hepatitis B status and associated factors among participants screened for simulated HIV vaccine efficacy trials in Kenya and Uganda
por: Mayanja, Yunia, et al.
Publicado: (2023)

Feasibility of conducting HIV prevention trials among key populations in Nairobi, Kenya
por: Mutisya, Elizabeth Mueni, et al.
Publicado: (2022)

Asymptomatic Mpox Virus Infection in Subjects Presenting for MVA-BN Vaccine
por: Matusali, Giulia, et al.
Publicado: (2023)

Prevalence and risk factors of three curable sexually transmitted infections among women in Nairobi, Kenya
por: Maina, Anne Njeri, et al.
Publicado: (2016)

Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals
por: Zaeck, Luca M., et al.
Publicado: (2022)

Ethnicity and Delay in Measles Vaccination in a Nairobi Slum
por: Ettarh, Remare R., et al.
Publicado: (2012)

Childhood vaccination in informal urban settlements in Nairobi, Kenya: Who gets vaccinated?
por: Mutua, Martin K, et al.
Publicado: (2011)

Multidrug-Resistant Bacterial Isolates Recovered from Herbal Medicinal Products Sold in Nairobi, Kenya
por: Korir, Richard, et al.
Publicado: (2017)

Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses
por: Wagstaffe, Helen R., et al.
Publicado: (2020)

Latent tuberculosis among household contacts of pulmonary tuberculosis cases in Nairobi, Kenya
por: Odera, Susan, et al.
Publicado: (2020)

Severe mpox (formerly monkeypox) disease in five patients after recent vaccination with MVA-BN vaccine, Belgium, July to October 2022
por: Berens-Riha, Nicole, et al.
Publicado: (2022)

Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial
por: Mpendo, Juliet, et al.
Publicado: (2020)

Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
por: Meseda, Clement A., et al.
Publicado: (2016)

Specificity of CD8(+) T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya
por: Mohamed, Yehia S., et al.
Publicado: (2020)

Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory
por: McLean, Chelsea, et al.
Publicado: (2023)

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
por: DeMaria, Peter J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8rp5uanmse543r1m98jjrr7eg7